MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.09), Zacks reports.
MoonLake Immunotherapeutics Trading Down 0.0 %
Shares of MoonLake Immunotherapeutics stock traded down $0.01 during trading hours on Friday, hitting $41.76. 302,843 shares of the company were exchanged, compared to its average volume of 439,783. The business has a 50-day moving average of $46.49 and a 200-day moving average of $48.94. MoonLake Immunotherapeutics has a 1 year low of $37.55 and a 1 year high of $58.26. The stock has a market capitalization of $2.67 billion, a price-to-earnings ratio of -32.37 and a beta of 1.28.
Analysts Set New Price Targets
Several research firms have commented on MLTX. Wedbush reaffirmed an "outperform" rating and set a $73.00 price objective (down from $92.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, November 5th. HC Wainwright reiterated a "buy" rating and set a $100.00 target price on shares of MoonLake Immunotherapeutics in a report on Thursday. The Goldman Sachs Group dropped their target price on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating on the stock in a report on Thursday. Finally, Needham & Company LLC increased their price target on shares of MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the company a "buy" rating in a research report on Thursday. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, MoonLake Immunotherapeutics currently has a consensus rating of "Buy" and an average target price of $83.20.
View Our Latest Analysis on MLTX
MoonLake Immunotherapeutics Company Profile
(
Get Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Recommended Stories
Before you consider MoonLake Immunotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MoonLake Immunotherapeutics wasn't on the list.
While MoonLake Immunotherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
